Clinical Effects of Safflower Pill of Dedu Seven Medicinal Herbs Plus Adefovir Dipivoxil on Liver Fibrosis Resulting from Chronic Viral Hepatitis B
International Journal of Biomedical Science and Engineering
Volume 5, Issue 3, June 2017, Pages: 24-28
Received: Jun. 6, 2017;
Published: Jun. 6, 2017
Views 2811 Downloads 151
Yi Na, College of Pharmacy, Inner Mongolia Medical University, Hohhot, P. R. China
Siwen Wei, College of Pharmacy, Inner Mongolia Medical University, Hohhot, P. R. China
Xiaoran Wang, College of Pharmacy, Inner Mongolia Medical University, Hohhot, P. R. China
Yi Wang, Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, P. R. China
Ruilian Ma, Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, P. R. China
Lidao Bao, Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, P. R. China
To study the clinical effects of Safflower Pill of Dedu Seven Medicinal Herbs combined with Adefovir Dipivoxil on liver fibrosis resulting from chronic viral hepatitis B.116 patients with chronic hepatitis B fibrosis were randomly divided into two groups (n=58 for each group): treatment group (Safflower Pill of Seven Medicinal Herbs combined with Adefovir Dipivoxil) and control group (Adefovir Dipivoxil) (n=58) for clinical observation of 24 weeks. After 24 weeks, the effective rates were 93.10% and 81.03% in the treatment group and control group respectively; the indexes of liver function, liver fibrosis and radiographic indexes of the patients in both groups were significantly decreased (P <0.05 or P <0.01); The differences between the two groups were statistically significant (P <0.05). The effect of Safflower Pill of Seven Medicinal Herbs combined with Adefovir Dipivoxil for the treatment of chronic hepatitis B fibrosis is more effective than that of Adefovir Dipivoxil alone.
Clinical Effects of Safflower Pill of Dedu Seven Medicinal Herbs Plus Adefovir Dipivoxil on Liver Fibrosis Resulting from Chronic Viral Hepatitis B, International Journal of Biomedical Science and Engineering.
Vol. 5, No. 3,
2017, pp. 24-28.
Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, et al. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis 2011;30:761-6.
Kikuchi H, Katsuramaki T, Kukita K, Taketani S, Meguro M, Nagayama M, et al. New strategy for the antifibrotic therapy with oral administration of FR260330 (a selective inducible nitric oxide synthase inhibitor) in rat experimental liver cirrhosis. Wound Repair Regen 2007;15:881-8.
Gong Y. Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine. Chin J Integr Med 2012;18:245-9.
Ba T, Bai WF, Wang H. [Clinical Observation on Treatment of Chronic Beta Particle Hepatitis with Two Kinds of Mongolian Medicine already Prepared by a Pharmacy for Main Dose of a Synthetical]. Liaoning Journal of Traditional Chinese Medicine 2004;32:391.
Hepatology of Chinese Medical Association. [Infectious Diseases credits will. Guide to prevention of chronic hepatitis B]. Journal of Hepatology 2005;12:881-9.
The China Association of Integrative Medicine Professional Committee of liver disease. [Integrative Medicine of liver fibrosis Guide]. Integrative Medicine on Liver Diseases 2006;16:316-20.
Zheng XY. [The guiding principles of Chinese medicine clinical research (for trial implementation)]. Beijing: Chinese Medical Science and Technology Press. 2002;44-150.
Tanikawa K. Serum marker for hepatic fibrosis and related liver pathology. Pathol Res Pract 1994;190:960-8.
Yao XX, Jiang SL, Tang YW, Yao DM, Yao X. Efficacy of Chinese medicine Yi-gan-kang granule in prophylaxis and treatment of liver fibrosis in rats. World J Gastroenterol 2005;11:2583-90.
Hu YY, Cheng Y. [Comprehensive therapy of chronic hepatitis B induced liver fibrosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008;28:765-8.
Ba T, Zhao ZX, Zhang GW. [Mongolian medicine Dedu saffron the -7 flavor scattered on the protective effect of acute liver injury and acute toxicity pharmacological tests]. Liaoning Journal of Traditional Chinese Medicine 2006;33:494.
Bai QY. [China Medical Encyclopedia (Mongolian Medicine)]. Shanghai: Shanghai Science and Technology Press. 1992;57.
Health of the People's Republic of China Pharmacopoeia Committee. [The Ministry of Health of the People's Republic of China pharmaceutical standards Mongolian Medicine Volume]. 1998.
Bai SY, Jason W, Wang AZ. [Expression of Serum IL_18 and Fas mRNA of Liver in Mice Hepatic Injury Model Induced by Dimethylnitrosamine]. Tianjin Traditional Chinese Medicine. 2003;31:787.
Zhang JN, Zhao YY, Chen BL, et al. [Bulging piece hepatic fibrosis clinical observation]. Chinese Integrative stomach magazine 1994;3:156-7.
Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, et al. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol 2011;46:1324-34.
Xie DY, Lin BL, Xu QH, Chen YM, Lu WL, Li JG, et al. [The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi 2008;16:341-4.
Zidek Z, Kmonickova E, Holy A. Cytotoxicity of pivoxil esters of antiviral acyclic nucleoside phosphonates: adefovir dipivoxil versus adefovir. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149:315-9.
Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update. J Gastroenterol Hepatol 2011;26:829-35.
Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol 2008;28:93-103.